Csl112 drug
WebJan 14, 2024 · CSL 112 - AdisInsight Drug Profile CSL 112 Alternative Names: ApoA-1; Apolipoprotein A-I - CSL Behring; CSL-112; CSL112 (reconstituted HDL) - CSL; CSL112 apo-AI; rHDL - CSL Latest Information Update: 14 Jan 2024 Price : $50 * Buy Profile Adis is an information provider. We do not sell or distribute actual drugs. WebThis is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse …
Csl112 drug
Did you know?
WebCSL112 is an intravenous preparation of human plasma-derived apoA-I formulated with phosphatidylcholine (PC). CSL112 is intended to improve CEC and thereby prevent early recurrent cardiovascular events following AMI. WebJun 26, 2014 · In the single ascending dose (SAD) study, 58 subjects were randomized to receive CSL112 or placebo in a 3:1 ratio, 57 received a dose of study drug, and 56 completed the study. One subject was withdrawn before dose administration and another was withdrawn after dose administration because of an adverse event.
WebFeb 14, 2024 · CSL Behring’s landmark AEGIS-II Phase 3 trial investigating CSL112 is the largest trial ever undertaken by our company and is the embodiment of our patient-first … WebThe CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. Am Heart J. 2024 Feb;208:81-90. doi: 10.1016/j.ahj.2024.11.008. Epub 2024 Nov 22.
WebCSL112 is a novel formulation of human apoA-I. The apoA-I is reconstituted with phosphatidylcholine to form disc-shaped HDL particles, each bearing 2 molecules of human apoA-I and 110 molecules of phosphatidyl-choline.22 CSL112 preparations contain sucrose as a stabilizing agent. In ex vivo studies, CSL112 was an efficient WebMar 22, 2024 · A third agent, CSL112, has advanced to phase 3 at a dose roughly 25-times higher than CER-001 and four-times higher than MDCO-216 . This trial in patients with acute coronary syndrome will examine time to subsequent major adverse cardiovascular event (cardiovascular death, myocardial infarction, or stroke) and is due to finish and be …
WebMar 26, 2024 · “CSL112 is an exciting new approach in cardiovascular medicine that may help protect our patients when they are most vulnerable.” Research showed that …
WebYou received your blood test result with a Cholesterol value of 112 mg/dL. This analysis helps you to check if your Cholesterol value is within normal range. Cholesterol 0 … how to scale in psWebAug 7, 2024 · CSL112 or placebo was administered as a single 2 h i.v. infusion into a suitable peripheral or central vein. Pharmacokinetics and pharmacodynamics of apoA-I ApoA-I concentration was assessed by an immunonephelometric method run on Roche Modular P at a specialty lipid laboratory (Pacific Biomarkers). how to scale in photoshop ccWebThis is a phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of CSL112 on reducing the risk of major adverse CV events [MACE - cardiovascular (CV) death, myocardial infarction (MI), and stroke] in subjects with acute coronary syndrome (ACS) diagnosed with either ST-segment … how to scale in pythonWebAug 25, 2015 · CSL112 resulted in rapid (T (max)≈2 hours) and dose-dependent increases in apoA-I (145% increase in the 6.8-g group) and total cholesterol efflux (up to 3.1-fold higher than placebo) (P<0.001). Conclusions: CSL112 infusion was well tolerated in patients with stable atherosclerotic disease. how to scale in rhino by percentWebCSL112 is a reconstituted, infusible human plasma-derived apolipoprotein A-I (apoA-I) that increases cholesterol efflux capacity – an ex vivo measure of the ability of HDL to accept cholesterol from macrophages. Areas covered: This article reviews the pharmacology of CSL112 and its current clinical development status. how to scale in revit 2023WebAug 7, 2024 · Abstract CSL112 (apolipoprotein A-I [apoA-I, ... CSL112 (apolipoprotein A-I [apoA-I, human]) is a novel drug in development to reduce the risk of recurrent cardiovascular events following acute myocardial infarction by increasing cholesterol efflux capacity (CEC). This phase I study aimed to compare the pharmacokinetics (PKs), … how to scale in powerpointWebCSL112 is a formulation of a naturally occurring protein called apolipoprotein A1, or apoA-I which regulates the process that flushes cholesterol out of the arteries and to the liver, … how to scale in sketchup using tape